Download Updated 2019 Prostate Cancer Patient Guide

Prostate Cancer Foundation’s goal is always to deliver the most cutting-edge treatments and information to families dealing with prostate cancer. As such, they have committed to updating the patient guide to reflect the very latest research and discoveries for patients. 

This is the second round of updates for 2019. Changes include:

  • Updated information on active surveillance
  • Revised guidance on when to start discussions of screening with physician aligned with NCCN recommendations (age 40 for African Americans, age 45 for average-risk men)
  • Additional details on indications for, and side effects of, second-generation anti-androgen drugs, including late-breaking approval of darolutamide for non-metastatic castration-resistant prostate cancer
  • Expanded section on treatment of metastatic hormone-sensitive prostate cancer
  • Information on commercially available genetic testing
  • Guidance on talking to your insurance company

Download an updated digital copy today and then be sure to provide feedback.

Updates on Clinical/Research Activities in Prostate Cancer at Stanford University

Dr. Andrei Iagaru, Professor of Radiology and Chief of the Division of Nuclear Medicine and Molecular Imaging at Stanford presented to our group about Nuclear Medicine at Stanford University and Updates on Clinical/Research Activities in Prostate Cancer on March 7, 2019.

Access the recording and presentation slides from the links below:

Excellent Blog Article on Biochemical Recurrence

A biochemical recurrence implies that an individual with prostate cancer who has already received therapy now has evidence of disease activity as reflected by a rising PSA.  This article by Dr. Maha Hussain does an excellent job of discussing this issue.  Click HERE to read this informative piece from Prostatepedia.

Overview of PET/CT Imaging in Recurrent Prostate Cancer – Current and Emerging Techniques

From Dr. Fabio’s blog post:

Over the last few years, we have seen tremendous activity in the area of molecular imaging for prostate cancer. Just about every day we have colleagues asking about the various PET/CT imaging tests – what is available?  How do they compare?  What are the parameters for successful imaging?

We are proud to have contributed to this body of knowledge. Our work regarding C11-Acetate PET/CT imaging in the recurrent PCa setting with relationship to PSA kinetics has been recently published – representing the largest single-site evaluation of a molecular imaging agent. A link to the publication and brief overview of PET/CT Imaging for Prostate Cancer follow for your review.  We hope you find this review useful.

Read the entire article on drfabio.com HERE

Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent disease

Prostate cancer–specific positron emission tomography (pcPET) has been shown to detect sites of disease recurrence at serum prostate-specific antigen (PSA) levels that are lower than those levels detected by conventional imaging. Commonly used pcPET radiotracers in the setting of biochemical recurrence are reviewed including carbon 11/fludeoxyglucose 18 (F-18) choline, gallium 68/F-18 prostate-specific membrane antigen (PSMA), and F-18 fluciclovine.

Note that this article mentions C-11 acetate briefly but does not cover it. Phoenix Molecular Imaging is not shown on the map of imaging centers.  Also, the study does not examine the significance of PSA doubling time, whereas it has been reported that short doubling time enhances detection with C11-Acetate even at very low PSA.

Read the entire article on sciencedirect.com HERE

Triple Hormonal Blockade (ADT3): A Patient’s Perspective

Opinion Article by Charles Maack

The information in this article is a lengthy read, but for men moved to androgen deprivation therapy the information is extremely important to be aware since everything explained may be involved in their well-being.

Triple-hormonal blockade/androgen deprivation therapy (ADT3) includes the prescribing of:

  1. a LHRH/GnRH agonist or antagonist to shut down testicular testosterone production
  2. an antiandrogen to block testosterone access to the cancer cell nucleus
  3. a 5Alpha Reductase (5AR) inhibitor to prevent any testosterone that might access the cancer cell nucleus from converting to dihydrotestosterone/DHT

Read the entire article on oncogen.org HERE